WVE supply chain intelligence for Wave Life Sciences Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Wave Life Sciences Ltd. (WVE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3 | GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3 | 90% | Pursuant to the GSK Collaboration Agreement, we and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics. |
| GLAXO-GROUP-LIMITED | GLAXO-GROUP-LIMITED | 85% | With respect to the $50.0 million equity investment, on December 13, 2022, we entered into a Share Purchase Agreement (the "GSK Share Purchase Agreement") with Glaxo Group Limited ("GGL"), an affilia… |
| SHIN-NIPPON-BIOMEDICAL-LABORATORIES-LTD | SHIN-NIPPON-BIOMEDICAL-LABORATORIES-LTD | 80% | Pursuant to the terms of various contract research service agreements with SNBL, a contract research organization and one of our shareholders, and its affiliates, we paid SNBL $4.0 million from Janua… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph:… |
| GLAXF | GSK plc | 72% | Reciprocal relationship from GLAXF graph: Reciprocal relationship from WVE graph: Reciprocal relationship from GLAXF graph: roup no longer holds the rights. The weighted average interest rate for cap… |
| MREO | Mereo BioPharma Group plc | 72% | Reciprocal relationship from MREO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from MREO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from MREO gra… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TRDA gra… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrup… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO gra… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | hich would increase the number of programs available to both parties. The Company will lead all preclinical research for GSK and the Company’s collaboration programs up to investigational new drug (“… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TKPHF … |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub… |
| CHIRALGEN-LTD | CHIRALGEN-LTD | 62% | ences USA, Inc. (“Wave USA”), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (“Wave Japan”), a company organized under the laws of Japan (formerly Chiralgen., Ltd… |
| WAVE-LIFE-SCIENCES-IRELAND-LIMITED | WAVE-LIFE-SCIENCES-IRELAND-LIMITED | 62% | ences USA, Inc. (“Wave USA”), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (“Wave Japan”), a company organized under the laws of Japan (formerly Chiralgen., Ltd… |
| WAVE-LIFE-SCIENCES-JAPAN-INC | WAVE-LIFE-SCIENCES-JAPAN-INC | 62% | ences USA, Inc. (“Wave USA”), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (“Wave Japan”), a company organized under the laws of Japan (formerly Chiralgen., Ltd… |
| WAVE-LIFE-SCIENCES-UK-LIMITED | WAVE-LIFE-SCIENCES-UK-LIMITED | 62% | ences USA, Inc. (“Wave USA”), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (“Wave Japan”), a company organized under the laws of Japan (formerly Chiralgen., Ltd… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| WVE-DEBT-13625 | Warrants outstanding: 46938000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| WVE-DEBT-13626 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2015-12-31. |
| WVE-DEBT | Debt stack $15.7M | 90% | Market cache reports total debt of $15.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| WVE-OWNER-RA-CAPITAL-MANAGEMENT-L-P | RA CAPITAL MANAGEMENT, L.P. | 90% | 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 237 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | 100.00 | 2 | |
| SLDB | Solid Biosciences Inc. | 100.00 | 2 | |
| TRDA | Entrada Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 100.00 | 2 | |
| SRRK | Scholar Rock Holding Corporation | 100.00 | 2 | |
| IBIO | iBio, Inc. | 100.00 | 1 | ['customer'] |
| KRRO | Korro Bio, Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| BMRN | BioMarin Pharmaceutical Inc. | 100.00 | 2 | |
| SRPT | Sarepta Therapeutics, Inc. | 100.00 | 2 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| HRMY | Harmony Biosciences Holdings, Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 1 | ['customer'] |
| GRFS | Grifols, S.A. | 100.00 | 2 | |
| RNA | Atrium Therapeutics, Inc. | 100.00 | 2 |